← The Wire
VNDANasdaq
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations · DE · CIK 1347178
Develops and commercializes innovative therapies for unmet medical needs using genetics and genomics
red 8-K · 90d
$353M
Market cap
$6.14
Last close
+2.2%
1D
+2.3%
5D
874K
Volume
Price · last 39 sessions-18.8%
May 4L $5.73 · H $7.56Jun 29
408
Total filings
Jun 5, 2026
Last filing
12/31
Fiscal year end
DEFA14ADEFA14AApr 23, 2026DEFA14ADEFA14AMay 27, 2025DEFA14ADEFA14AApr 25, 2025DEFA14ADEFA14AMay 13, 2024DEFA14ADEFA14AMay 9, 2024DEFA14ADEFA14AApr 24, 2023DEFA14ADEFA14AApr 25, 2022DEFA14ADEFA14AApr 22, 2021DEFA14ADEFA14AMay 26, 2020DEFA14ADEFA14AApr 22, 2020DEFA14ADEFA14AApr 25, 2019DEFA14ADEFA14AJun 1, 2018DEFA14ADEFA14AApr 27, 2018DEFA14ADEFA14AApr 27, 2017DEFA14ADEFA14AApr 28, 2016DEFA14ADEFA14AApr 29, 2015DEFA14ADEFINITIVE ADDITIONAL MATERIALSApr 7, 2014DEFA14ADEFA14AApr 26, 2013DEFA14ADEFA14AApr 30, 2012DEFA14ADEFA14AApr 29, 2011
Insider Activity
In the 90 days to Mar 2, 2026: 6 sold $2.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Polymeropoulos Mihael HristosPresident and CEO | Sell | 156,235 | $8.17 | $1.3M |
| Mar 2, 2026 | Moran Kevin PatrickSVP, CFO & Treasurer | Sell | 42,442 | $8.27 | $351K |
| Mar 2, 2026 | Williams TimothySVP & General Counsel | Sell | 42,434 | $8.27 | $351K |
| Mar 2, 2026 | Birznieks GuntherSVP, Business Development | Sell | 42,431 | $8.27 | $351K |
| Mar 2, 2026 | Wijkstrom JoakimSVP, Chief Marketing Officer | Sell | 30,800 | $8.27 | $255K |
| Feb 23, 2026 | Honore TageDirector | Sell | 30,000 | $8.03 | $241K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance